DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Squamous Cell Carcinoma of the Head and Neck – Geographic Focus: China – China In-Depth – Squamous Cell Carcinoma of the Head and Neck
China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Current Treatment: Physician Insights – Squamous Cell Carcinoma of the Head and Neck (US)
The treatment of non-nasopharyngeal SCCHN is heterogeneous and guided by multiple factors, such as tumor burden and growth, the line of therapy, and prior treatment exposure. In the locoregionally…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Treatment Sequencing – Squamous Cell Carcinoma of the Head and Neck (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2025
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Squamous Cell Carcinoma of the Head and Neck – Unmet Need – Unmet Need – Recurrent or Metastatic Non-Nasopharyngeal Squamous Cell Carcinoma of Head and Neck (US/EU)
Recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck is an aggressive malignancy associated with a high recurrence rate. The approval of immune checkpoint…
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC (US/EU)
Approximately 20% of nonsquamous NSCLC in Western patients is driven by mutations in EGFR, and as such is treated predominantly with agents targeting those alterations. The market is currently…
Squamous Cell Carcinoma of the Head and Neck – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of SCCHN comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of SCCHN for each country, as…
Squamous Cell Carcinoma of the Head and Neck – Epidemiology – Extrapolated worldwide coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key squamous cell carcinoma of the head and neck patient populations,…
